Shandong Lukang Pharmaceutical (SHA:600789) obtained drug registration certificates from China's National Medical Products Administration for the active pharmaceutical ingredient, imatinib mesylate, according to a Shanghai bourse filing on Wednesday.
The Chinese pharmaceutical company's shares slipped 1% at the close.
The API is used for patients with Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.